ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201580
CHEMBL1201580
Compound Name ADALIMUMAB
ChEMBL Synonyms ADALIMUMAB | D2E7 | LU-200134 | HUMIRA
Max Phase 4 (Approved)
Trade Names HUMIRA

Sources

  • British National Formulary
  • Clinical Candidates
  • Manually Added Drugs
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL1201580 compound icon
Drug Type:Antibody Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
TNF-alpha inhibitor TNF-alpha DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Arthritis, JuvenileD001171EFO:0002609chronic childhood arthritis3ClinicalTrials
Dupuytren ContractureD004387EFO:0004229Dupuytren Contracture2ClinicalTrials
Glomerulosclerosis, Focal SegmentalD005923EFO:0004236focal segmental glomerulosclerosis2ClinicalTrials
OsteoarthritisD010003EFO:0002506osteoarthritis3ClinicalTrials
PyodermaD011711HP:0000999pyoderma3ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis3ClinicalTrials
Behcet SyndromeD001528EFO:0003780Behcet's syndrome3ClinicalTrials
Giant Cell ArteritisD013700EFO:1001209temporal arteritis3ClinicalTrials
Spondylitis, AnkylosingD013167EFO:0003898ankylosing spondylitis3ClinicalTrials
AsthmaD001249EFO:0000270asthma2ClinicalTrials
SciaticaD012585HP:0011868Sciatica2ClinicalTrials
Hidradenitis SuppurativaD017497EFO:1000710hidradenitis suppurativa3ClinicalTrials
Netherton SyndromeD056770Orphanet:634Netherton syndrome2ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis3ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma1ClinicalTrials
ColitisD003092EFO:0003872colitis2ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease3ClinicalTrials
SarcoidosisD012507Orphanet:797Sarcoidosis2ClinicalTrials
UveitisD014605EFO:1001231uveitis3ClinicalTrials
Arthritis, PsoriaticD015535EFO:0003778psoriatic arthritis3ClinicalTrials
Immune System DiseasesD007154EFO:0000540immune system disease4ATC
Colitis, UlcerativeD003093EFO:0000729ulcerative colitis3ClinicalTrials
Cystitis, InterstitialD018856EFO:1000869chronic interstitial cystitis3ClinicalTrials
MucopolysaccharidosesD009083Orphanet:79213Mucopolysaccharidosis1ClinicalTrials

Clinical Data

ClinicalTrials.gov ADALIMUMAB
The Cochrane Collaboration ADALIMUMAB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 - IMMUNOSUPPRESSANTS
L04A - IMMUNOSUPPRESSANTS
L04AB - Tumor necrosis factor alpha (TNF-α) inhibitors
L04AB04 - adalimumab

ChemSpider ChemSpider Identifier not yet assigned
DailyMed adalimumab
Wikipedia Adalimumab
spacer
spacer